Short-term outcomes of intravesical heparin therapy for bladder pain syndrome; a single-blinded randomized controlled trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180912004

Enrollment

Registered

2018-09-12

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder pain syndrome Bladder pain syndrome Intravesical heparin instillation Efficacy

Interventions

Comparison between intravesical heparin instillation with conservative treatment and Conservative treatment alone,Comparison between intravesical heparin instillation with conservative treatment and C

Experimental Drug,Experimental Behavioral

Intravesical heparin instillation,Control

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Bladder pain syndrome VAS >/= 4

Exclusion criteria

Exclusion criteria: Allergy to heparin History of gross hematuria History of coagulopathy Pregnancy and lactation Patients who have received previous treatment for bladder pain syndrome

Design outcomes

Primary

Measure	Time frame
Severity of pain at 12 week after treatment Visual analog scale	—

Secondary

Measure	Time frame
Daytime frequency of urination at 12 week after treatment Frequency volume chart,Quality of life at 12 week after treatment PUF questionnaire,Side effect of intravesical heparin at 12 week after treatment Question	—

Countries

Thailand

Contacts

Public ContactChutimon Asumpinwong

Siriraj Institutional Review Board

chutata@hotmail.com+6624194782

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Short&#45;term outcomes of intravesical heparin therapy for bladder pain syndrome; a single&#45;blinded randomized controlled trial